![Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis – Adaptive Phage Therapeutics Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis – Adaptive Phage Therapeutics](https://aphage.com/v3/wp-content/uploads/2022/05/Picture1-2-1024x572.jpg)
Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis – Adaptive Phage Therapeutics
![Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors | BioBuzz Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors | BioBuzz](https://biobuzz.io/wp-content/uploads/2019/10/Adaptive-Phage-Team-scaled.jpg)
Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors | BioBuzz
![Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill 'Superbugs' as Part of Bear's Den Innovation Program Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill 'Superbugs' as Part of Bear's Den Innovation Program](https://mma.prnewswire.com/media/1038925/Adaptive_Phage_Therapeutics.jpg?p=facebook)
Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill 'Superbugs' as Part of Bear's Den Innovation Program
![Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund - Microbiome Times Magazine Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund - Microbiome Times Magazine](https://www.microbiometimes.com/wp-content/uploads/2022/04/shutterstock_1251867076-678x381.jpg)
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund - Microbiome Times Magazine
![Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections | BioSpace Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections | BioSpace](https://mms.businesswire.com/media/20201022005487/en/832661/4/IMG_9425_webready.jpg)
Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections | BioSpace
![Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial | BioBuzz Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial | BioBuzz](https://biobuzz.io/wp-content/uploads/2022/10/ddbfb119-8d60-46dc-820c-b74d405e8100.jpg)
Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial | BioBuzz
![Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis | Business Wire Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis | Business Wire](https://mms.businesswire.com/media/20210310005077/en/864139/23/New_APT_Logo_-_03.09.21.jpg)
Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis | Business Wire
![Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors – BioHealth Capital Region Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors – BioHealth Capital Region](http://www.biohealthcapital.com/wp-content/uploads/2018/12/adaptive-phage-therapeutics-inc_owler_20180207_133539_original.png)
Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors – BioHealth Capital Region
![Gaithersburg's Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection - The MoCo Show Gaithersburg's Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection - The MoCo Show](https://mocoshow.com/wp-content/uploads/2023/01/Screen-Shot-2023-01-13-at-3.57.31-PM.png)